Cephalalgia · 2023 · 18 citations · 18 references
PharmacyPharmacotherapyPreventive MedicineClinical PharmacologyPain MedicinePharmacovigilanceChronic Disease PharmacotherapyHeadache AssessmentHeadache DisordersHeadache ManagementMigraine PharmacotherapyAcute Adverse EventsAcute Migraine TreatmentChronic HeadacheInterim AnalysisPreventive Headache TherapyPreventive Migraine TherapyPreventive Migraine TreatmentReal-world Comparative Effectiveness
BACKGROUND: The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. METHODS: Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1-12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1-12. Safety was assessed through adverse events reported. RESULTS: Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1-12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. CONCLUSION: PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries.Trial registration: encepp.eu: EUPAS35111.
18
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal et al. · New England Journal of Medicine · 2017 · 803 citations · Full text
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal et al. · JAMA · 2018 · 573 citations · Full text
Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet · 2019 · 434 citations
Andrew Blumenfeld, Lisa Bloudek, Werner J. Becker et al. · Headache The Journal of Head and Face Pain · 2013 · 390 citations